Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SANDOSTATIN
- Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
- Real-world Study on Adjuvant Octreotide Therapy in pNETs
- A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
- Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients With Esophageal or Gastric Cancer
- Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
- A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
- Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers
- Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients
- Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
- Assessment of Intranasal Glucagon on Endogenous Glucose Production
- Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET
- Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy
- Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
- Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
- Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias
- The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
- Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
- Effects of Glucagon Administration on Energy Expenditure
- Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
- Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
- Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
- Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
- Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
- Ghrelin Suppression by Octreotide in Prader-Willi
- Acromegaly Combination Treatment Study
- Effects of Sandostatin LAR® in Acromegaly
- Surgical Debulking of Pituitary Adenomas
- Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis
- Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
- Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S
- Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
- Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
- Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
- Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
- Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
- Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
- Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
- Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
- Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
- Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
- The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
- Preoperative Octreotide Treatment of Acromegaly
- Sandostatin for Patients With Androgen Independent Prostate Cancer
- Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
- Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
- Estrogen Treatment in Acromegalic Women
- Treatment of Orthostatic Intolerance
- Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
- Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
- Stress, Diurnal Cortisol, and Breast Cancer Survival
- Treatment of Orthostatic Hypotension in Autonomic Failure
- Octreotide in Treating Patients With Cancer-Related Malignant Ascites
- Prader-Willi Syndrome and Appetite
- An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
- Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
- Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
- Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
- Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
- Pegvisomant And Sandostatin LAR Combination Study
- STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
- Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
- Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
- Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
- A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Co
- A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
- Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
Clinical trials list
click for details